ReNeuron Group plc
("ReNeuron" or the "Company")
Share Purchase by a Director
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed that on the 20 October 2021, the following purchase of the Company's ordinary shares of 1p each ("Ordinary Shares") was made by a director of the Company:
|
Name |
Title |
Number of Ordinary Shares purchased |
Total beneficial interest in the Company's Ordinary Shares |
Percentage of Company's Total Voting Rights |
|
Barbara Staehelin |
Senior Independent Non-Executive Director |
43,000 |
43,000 |
0.08% |
ENDS
Contacts:
|
ReNeuron |
|
|
Olav Hellebø, Chief Executive Officer Catherine Isted, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace |
+44 (0)20 7710 7600
|
|
|
|
|
Allenby Capital Limited (Joint Broker) |
+44 (0)20 3328 5656 |
|
James Reeve/George Payne (Corporate Finance) |
|
|
Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to share options granted to Directors and PDMRs)
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Barbara Staehelin |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Senior Independent Non-Executive Director |
||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
ReNeuron Group plc |
||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares 1p RENE - GB00BF5G6K95 |
||||
|
b) |
Nature of the transaction |
Acquisition of ordinary shares |
||||
|
c) |
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information |
£49,450 |
||||
|
e) |
Date of the transaction |
20 October 2021 |
||||
|
f) |
Place of the transaction |
London Stock Exchange AIM Market |
||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
